SLC5A2 and hydrops fetalis: No new safety signals emerged, with SGLT2 inhibitors generally well tolerated.<h4>Conclusion</h4>Real-world SGLT2 inhibitor use significantly reduces hospitalisations and mortality across diverse HF phenotypes, mirroring trial results.